Stacy Lane
Infectious Disease · Pittsburgh, PANPI 1568681336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Viiv Healthcare Company at 40.6% of the total. Reporting peaked in 2019 at $1,356 and has fallen 85.3% since, to $200 in 2025.
Across 252 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- AbbVie$703
- Merck$305
- Indivior Inc.$262
- Johnson & Johnson$152
- plus $566 from 15 others
Across 2 payments — averaging $7020.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$14K
What the payments were for
- Food & beverage$5,66099%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 124 | $2,323 |
| Gilead | 49 | $1,406 |
| AbbVie | 22 | $703 |
| Merck | 17 | $305 |
| Indivior Inc. | 9 | $262 |
| Johnson & Johnson(2 entities) | 6 | $152 |
| Antares Pharma, Inc. | 1 | $122 |
| Theratechnologies Inc. | 4 | $108 |
| EMD Serono, Inc. | 6 | $90 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $26 |
| Alkermes, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Mylan Institutional Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,716 in reported general payments places this provider in the 85th percentile of 457 infectious disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,457 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Pittsburgh
- Amesh AdaljaPittsburgh$415K
- Micah JacobsPittsburgh$206K
- Brandon SmithPittsburgh$108K
- Lee HarrisonPittsburgh$70K
- Yohei DoiPittsburgh$67K
- Chiu Bin HsiaoPittsburgh$33K
- Minh-Hong NguyenPittsburgh$20K
- Ghady HaidarPittsburgh$19K
- Thomas WalshPittsburgh$10K
- Fernanda SilveiraPittsburgh$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.